Clinical Trials
4
Active:2
Completed:1
Trial Phases
2 Phases
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)โข Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 3
1 (25.0%)FOLFOXIRI With or Without Intensification for Rectal Cancer
Phase 2
Recruiting
- Conditions
- Rectal Cancer
- Interventions
- Drug: Control armDrug: Experimental arm
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- CCTU
- Target Recruit Count
- 72
- Registration Number
- NCT03997435
- Locations
- ๐ญ๐ฐ
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
๐ญ๐ฐDepartment of Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong
๐ญ๐ฐThe Chinese University of Hong Kong, Hong Kong, Hong Kong
SRAM Study_Postate Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced Prostate Cancer
- Interventions
- Radiation: Conventional IMRTDrug: SBRT
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- CCTU
- Target Recruit Count
- 120
- Registration Number
- NCT03938649
- Locations
- ๐ญ๐ฐ
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Pembrolizumab in Hepatocellular Carcinoma
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- CCTU
- Target Recruit Count
- 30
- Registration Number
- NCT03419481
- Locations
- ๐ญ๐ฐ
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- CCTU
- Target Recruit Count
- 120
- Registration Number
- NCT03079219
- Locations
- ๐ญ๐ฐ
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
News
No news found